December 26, 2019 5:32pm

Trading volumes moved the downside, 8 out of the 16 upside had higher than the 3 month average volume> while 3 out of 20 downside had low volume than the 3 month average volume

From the pre-open: “without being a kill-joy – SELL into strength!”

Pre-open indications: 4 HITs < SELL into strength – ADRO (+$0.05), ADVM (+$0.27), AGTC (+$0.06) while CLLS (+$0.18) was oversold> 0 MISS

Be safe if traveling and open to new motivation for portfolio return from RMi


 

The Dow closed up +105.94 points (+0.37%), the S&P closed up +16.53 points (+0.51%) and the NASDAQ closed UP +69.51 points (+0.78%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday the IBB closed down -0.92% while and XBI closed down -0.85%
  • Wednesday markets were closed;
  • Tuesday the IBB closed up +0.58% while and XBI closed up +0.75%
  • Monday the IBB closed up +0.87% while and XBI closed up +1.01%

 

The advance/decline line scenario of 45 covered companies:

  • Thursday the close was negative with an A/D line of 16/20, 2 flats, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);
  • Wednesday was Christmas Day;
  • Tuesday the close was positive with an A/D line of 27/10, 1 flat, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);
  • Monday the close was positive with an A/D line of 33/5, 1 flat, 2 reversed merged (HSGX & ONVO), 2 dropped (BTX and CUR) and 3 acquired (ONCE, AST & OSIR);

 

Henry’omics:

Indexes climbed Thursday, hitting record highs as the market rallied into the end of 2019 while the sector found coal in their stockings.

Defining the bottom was an Advance/decline (A/D) line of 16/20 led by: bluebird bio (BLUE -$4.68), Sage Therapeutics (SAGE -$2.64), ReNeuron (RENE.L -$1.00), Voyager Therapeutics (VYGR -$0.79) and Regenxbio (RGNX -$0.61).

While the upside was lifted by:  uniQure NV (QURE +$1.01), Global Blood Therapeutics (GBT +$0.59), ThermoGenesis (KOOL +$0.35), Adverum (ADVM +$0.27) and Audentes Therapeutics (BOLD +$0.25).

The NASDAQ topped the 9,000 mark for the first time ever. Three major averages all hit new all-time highs. Trading volumes remained thin this week.

The S&P 500 notched its 34th record close Thursday. The benchmark has risen 3.1% this month and 8.8% this quarter, bringing the year-to-date gains to 29.2%. The S&P 500 has a good chance at scoring a historic year: It is now less than 1 percentage point from posting the best annual performance since 1997 <CNBC>.

From the pre-open, “In a shortened Christmas week, sporadic trading will occur as many remain home or travel bound or just complacent enjoying family and down time. Without being a kill-joy – SELL into strength …!”

From this a.m.’s “Data Docket”- U.S. weekly jobless claims decreased 13,000 to a seasonally adjusted 222,000 for the week ended Dec. 21, the Labor Department said Thursday. The number is slightly higher than estimates of 220,000 in a Dow Jones poll of economists <CNBC>.

Markets in Europe, Australia and Hong Kong remained closed.

 

Selling the highs has an advantage (excluding the tax consequense for risk consideration) ...  for bargains will be available toward the end of January post the JPMorgan healthcare conference in early January and the anxiliary mini conferences during the time frame!

 

Decliners:

  • bluebird bio (BLUE -$4.68 after Tuesday’s +$5.44 after Monday’s -$2.54);
  • Sage Therapeutics (SAGE -$2.64 after Tuesday’s +$2.16);
  • ReNeuron (RENE.L -$1.00 after Tuesday’s -$1.00 after Monday’s +$3.50);
  • Voyager Therapeutics (VYGR -$0.79);
  • Regenxbio (RGNX -$0.61);

Incliners:

  • uniQure NV (QURE +$1.01 after Tuesday’s +$1.78 after Monday’s +$2.47 and last  Friday’s -$0.63);
  • Global Blood Therapeutics (GBT +$0.59 after Tuesday’s +$1.04 after Monday’s +$3.36 and Friday’s +$1.060;
  • ThermoGenesis (KOOL +$0.35);
  • Adverum (ADVM +$0.27);
  • Audentes Therapeutics (BOLD +$0.25)

 

The percentage (%) indicators:

  • Thursday’s range of the 16 upside was +0.05% (AXGN) to +12.28% (BLCM) while the 20 downside ranged from -0.06% (BMRN) to -7.90% (XON); 
  • Wednesday markets were closed; 
  • Tuesday closed POSITIVE with 10 decliners, 27 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);
  • Monday’s range of the 32 upside was +0.14% (MDXG) to +11.22% (ADRO) while the 5 downside ranged from -0.08% BLUE) to -0.73% (SAGE); 

 

Upside volume stats:  to compare

  • Thursday: 8 out of the 16 upside had higher than the 3 month average volume;
  • Wednesday: markets closed;
  • Tuesday: 5 out of the 27 upside had higher than the 3 month average volume;
  • Monday: 9 out of the 35 upside had higher than the 3 month average volume;

Downside volume stats:

  • Thursday: 3 out of the 20 downside had higher than the 3 month average volume;
  • Wednesday: markets closed;
  • Tuesday: 2 out of the 10 downside had higher than the 3 month average volume;
  • Monday: 1 out of the 2 downside had higher than the 3 month average volume;
  • Friday: 12 out of the 19 downside had higher than the 3 month average volume;

 

2 flat –BSTG and CLBS

 

December’s sessions:

Thursday closed NEGATIVE with 20 decliners, 16 advancers, 2 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Wednesday markets were closed;

Tuesday closed POSITIVE with 10 decliners, 27 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Monday closed POSITIVE with 2 decliners, 35 advancers, 1 flat, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 19 decliners, 15 advancers, 3 flats, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Thursday closed POSITIVE with 12 decliners, 24 advancers, 2 flats, 2 dropped (BTX & CUR) and 3 acquired (ONCE, AST & OSIR) and 2 reversed (HSGX & ONVO);

Wednesday closed NEGATIVE with 23 decliners, 13 advancers, 3 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Tuesday closed NEGATIVE with 22 decliners, 16 advancers, 1 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Monday closed POSITIVE with 13 decliners, 25 advancers, 1 flat, 2 dropped (BTX & CUR) and 2 acquired (AST & OSIR) and 2 reversed (HSGX & ONVO);

Friday closed NEGATIVE with 24 decliners, 16 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 0 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed NEGATIVE with 13 decliners, 27 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 17 decliners, 22 advancers, 2 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Friday closed POSITIVE with 9 decliners, 29 advancers, 3 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Thursday closed NEGATIVE with 31 decliners, 9 advancers, 1 flat, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Wednesday closed POSITIVE with 13 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Tuesday closed POSITIVE with 12 decliners, 25 advancers, 4 flats, 1 dropped (BTX) and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

Monday closed NEGATIVE with 26 decliners, 19 advancers, 2 flats and 2 acquired (AST & OSIR) and 1 reversed (HSGX);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.